Pacira Biosciences

Pacira BioSciences reported Q2 2026 revenue of $192.4 million, above the consensus estimate of $191.06 million. EXPAREL remained the main revenue driver; ZILRETTA and iovera° also grew, and iovera° was sold to Zimmer Biomet at the end of July. Non‑GAAP gross margin fell to 78% and the company adjusted its full‑year revenue guidance to $735–760 million. Pacira highlights strong liquidity ($251 million before a $70 million prepayment) and points to several upcoming clinical data catalysts in the second half of the year. » More on de.investing.com

Pacira BioSciences has agreed to sell its iovera° division to Zimmer Biomet for a $70 million upfront payment plus up to $70 million in revenue‑based milestones through the end of 2031. Zimmer Biomet will assume rights to the development, manufacture and commercialization of the FDA‑approved cryoneurolytic iovera° system. Pacira intends to use the net proceeds to strengthen its balance sheet and to repay a revolving credit facility; the transaction is expected to close in Q3 2026. Both companies will continue to collaborate on the spasticity program, with Pacira eligible for additional payments if the study and regulatory approval are successful. » More on de.investing.com

DOMA Perpetual, a shareholder with about a 7.5% stake in Pacira, has nominated three directors for the annual meeting on June 9 and is urging the board to explore strategic alternatives, including a sale. The investor criticizes Pacira’s strategic approach and stock performance (down 54% over ten years, currently $22.47, market capitalization $884 million) and points to patent disputes with generic manufacturers. Pacira derives roughly 80% of revenue from the pain drug EXPAREL, reported 4% revenue growth in 2025, saw sharply higher R&D and administrative expenses, but has a high gross margin (79%) and a Piotroski score of 9. » More on de.investing.com